CONMED Corporation 2013 Form 10-K Summary
Business context and reporting period
CONMED is a medical technology company focused on surgical devices and equipment for minimally invasive procedures and monitoring. Products serve orthopedic, general surgery, gynecology, neurosurgery and gastroenterology markets and are sold in more than 100 countries. The filing covers the fiscal year ended December 31, 2013; quarterly data for the fourth quarter is also provided. Effective January 1, 2013, CONMED began reporting as a single operating segment.
- Approximately 80% of revenue came from single-use disposable products and approximately 20% from capital products.
- International customers represented approximately 51% of 2013 sales; approximately 36% of total sales were denominated in local currencies.
- 2013 product mix: orthopedic surgery 54%, general surgery 37% and surgical visualization 9% of net sales.
Key financial metrics
| Metric | 2013 | 2012 | Change |
|---|---|---|---|
| Net sales | $762.7 million | $767.1 million | Down 0.6% |
| Gross profit | $412.4 million | $405.8 million | Up 1.6% |
| Gross margin | 54.1% | 52.9% | Up 1.2 percentage points |
| Income from operations | $56.5 million | $65.2 million | Down 13.3% |
| Operating margin | 7.4% | 8.5% | Down 1.1 percentage points |
| Net income | $35.9 million | $40.5 million | Down 11.2% |
| Diluted EPS | $1.28 | $1.41 | Down 9.2% |
| Operating cash flow | $80.9 million | $95.2 million | Down 15.0% |
| Capital expenditures | $18.4 million | $21.5 million | Down 14.3% |
Cost of sales declined to $350.3 million from $361.3 million, primarily reflecting restructuring-related cost reductions. Selling and administrative expense increased to $310.7 million, or 40.7% of sales, from $302.5 million, or 39.4%. Research and development expense declined to $25.8 million from $28.2 million. The effective tax rate was 29.0%, compared with 31.9% in 2012.
Fourth-quarter 2013 sales were $203.4 million, gross profit was $111.4 million and net income was $10.2 million, compared with fourth-quarter 2012 sales of $201.2 million, gross profit of $107.3 million and net income of $10.9 million. Fourth-quarter diluted EPS was $0.36 versus $0.38.
Liquidity, debt and capital allocation
- Cash and cash equivalents were $54.4 million at December 31, 2013, including approximately $45.2 million held by foreign subsidiaries.
- Net working capital was $260.9 million.
- Total debt was $215.6 million, or approximately 21% of total capitalization, including $208.0 million outstanding under a $350.0 million revolving credit facility and $7.6 million of mortgage debt.
- Available revolving credit capacity was $134.2 million, with approximately $7.8 million reserved for letters of credit. The company was in compliance with its debt covenants.
- Operating cash flow funded capital expenditures, debt service, dividends and share repurchases. 2013 financing cash flow was a use of $31.3 million, including $50.6 million of share repurchases, $34.0 million paid under the MTF agreement and $16.7 million of dividends.
- The company repurchased 1.6 million shares for $50.6 million in 2013. Remaining authorization at year-end was $54.3 million under the $200.0 million program.
- The quarterly dividend was increased from $0.15 to $0.20 per share in October 2013; 2013 dividends were $0.65 per share.
Material changes versus the prior comparable period
- Revenue declined modestly because of lower orthopedic surgery and surgical visualization sales. General surgery sales were essentially flat.
- Orthopedic sales declined 0.9% to $410.2 million, while surgical visualization declined 1.2% to $65.8 million. General surgery sales increased 0.0% to $286.7 million.
- Capital equipment sales declined 1.4% to $153.7 million; single-use product sales declined 0.4% to $609.0 million.
- Gross margin improved 1.2 percentage points, but higher selling and administrative costs, the new medical device excise tax and other expenses reduced operating and net margins.
- The 2.3% U.S. medical device excise tax resulted in a $5.9 million expense, approximately 0.8% of global sales.
- Other expense increased to $13.4 million from $10.0 million, including $8.8 million of administrative consolidation costs, $3.2 million of patent-dispute legal costs and $1.4 million of pension settlement expense.
- Operating cash flow decreased by $14.3 million, primarily due to medical device excise-tax payments and working-capital changes.
- Debt increased substantially following refinancing and borrowings used to fund the MTF agreement; the company recorded a $0.3 million loss on early extinguishment of debt.
Guidance, outlook, commentary and risks
- Management was cautiously optimistic about improving domestic economic conditions but noted continuing challenges in Europe and other international markets.
- 2014 capital expenditures were expected to approximate $20.0 million.
- Remaining contingent payments under the MTF agreement totaled $50.0 million at year-end, including $16.7 million paid in January 2014; the remaining payments are expected to be funded with cash and revolver capacity over approximately three years.
- The company expected approximately $4.0 million to $5.0 million of 2014 restructuring and related legal costs. A new restructuring phase announced in February 2014 will consolidate Centennial, Colorado manufacturing operations over the following 24 months; total costs had not yet been determined.
- An FDA inspection of the Centennial facility resulted in a September 2013 Form 483 and a January 30, 2014 Warning Letter. Remediation costs were not expected to be material, but potential recalls, additional regulatory action, fines or production restrictions could not be excluded.
- CONMED faces risks from healthcare cost containment, competitive pricing, changing procedure volumes, foreign currency movements, regulatory compliance, product recalls, patent litigation, raw-material availability, acquisitions and variable-rate debt.
- A 1.0 percentage-point change in average 2014 market interest rates was estimated to change annual interest expense and pretax income by approximately $2.1 million, assuming no debt repayments.
- The Bonutti Skeletal Innovations patent lawsuit remained unresolved, and a range of potential losses could not be estimated.
Important facts for investors to verify
- Progress, costs and timing of the Centennial facility consolidation and other restructuring initiatives.
- Resolution and financial exposure from the FDA Warning Letter, potential recalls and other regulatory actions.
- Outcome and potential costs of the Bonutti patent litigation.
- Ability to fund the $50.0 million of remaining MTF contingent consideration while maintaining covenant compliance and liquidity.
- Impact of foreign exchange, international demand and healthcare-provider purchasing constraints on revenue growth.
- Effect of variable interest rates on debt service and the company’s ability to refinance or repay significant 2018 maturities.
- Sustainability of gross-margin gains given elevated selling and administrative expenses and continued pricing pressure.